has anyone been able to contact the company and get a word on why this has been delayed to 1st quarter next year? (tried several times... no reply)
initially claimed approval for T315I would come end of this year.
why is chemgenex confident European regulators will have no concerns with the mutation tests used in Study 202? (as per FDA in March this year). will they also want a single validated test on market?
Cephalon coming on board has given me a bit more conifdence in the stock. I've always felt the massive sell-off in March this year was way overdone, and picked up a lot of shares. But can never be too confident with biotechs.
btw .. anyone able to go to the AGM on Monday 29th?
Add to My Watchlist
What is My Watchlist?